Array Biopharma, Inc. (ARRY) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.69 +8.85%
Revenue Growth %: -18.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
LTBR, AES, SYRS, More
Revenue Growth %: -18.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
On Monday, Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $15.8 million versus the consensus estimate of $16.7 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley bearish on Coinbase, slashes target on weaker recovery
- US Lime and Minerals (USLM) PT Lowered to $131 at Freedom Broker
- Alphabet shares rise as analysts back stock after selloff
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
